Travere Therapeutics (TVTX) Amortization of Deferred Charges (2014 - 2022)

Travere Therapeutics' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $428000.0 for Q4 2022.

• Quarterly Amortization of Deferred Charges fell 85.17% year-over-year to $428000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.6 million (down 73.28% YoY) and the FY2025 annual result came in at $1.6 million, down 4.93% from the prior year.
• Amortization of Deferred Charges was $428000.0 for Q4 2022 at Travere Therapeutics, roughly flat from $428000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $9.2 million in Q4 2020 and bottomed at $50000.0 in Q3 2018.
• A 5-year average of $1.8 million and a median of $428000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges soared 429.4% — and 2022, when it tumbled 87.65%.
• Travere Therapeutics' Amortization of Deferred Charges stood at $2.3 million in 2018, then surged by 284.1% to $8.8 million in 2019, then gained by 4.84% to $9.2 million in 2020, then tumbled by 68.61% to $2.9 million in 2021, then slumped by 85.17% to $428000.0 in 2022.
• Business Quant data shows TVTX's Amortization of Deferred Charges at $428000.0 in Q4 2022, $428000.0 in Q3 2022, and $429000.0 in Q2 2022.